

Cabatuan Nelson
Form 3
December 22, 2017

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Cabatuan Nelson</p> <p>(Last) (First) (Middle)</p> <p>RIGEL PHARMACEUTICALS, INC., Â 1180 VETERANS BLVD.</p> <p>(Street)</p> <p>SOUTH SAN FRANCISCO, Â CA Â 94080</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>12/18/2017</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>RIGEL PHARMACEUTICALS INC [RIGL]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p>____ Director ____ 10% Owner <input checked="" type="checkbox"/> Officer ____ Other (give title below) (specify below) Principal Accounting Officer</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p>
---	---	--	---	---	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	58	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	--	--

Edgar Filing: Cabatuan Nelson - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â <u>(1)</u>	11/13/2018	Common Stock	1,212	\$ 6.48	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	03/30/2019	Common Stock	3,250	\$ 6.49	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	02/01/2021	Common Stock	5,000	\$ 6.73	D	Â
Stock Option (right to Buy)	Â <u>(1)</u>	02/01/2021	Common Stock	5,000	\$ 6.73	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	01/25/2022	Common Stock	10,000	\$ 8.15	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	01/30/2023	Common Stock	2,500	\$ 6.51	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	09/19/2023	Common Stock	6,000	\$ 3.55	D	Â
Stock Option (Right to Buy)	Â <u>(2)</u>	01/29/2024	Common Stock	10,000	\$ 3.2	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	01/29/2024	Common Stock	6,500	\$ 3.2	D	Â
Stock Option (Right to Buy)	Â <u>(3)</u>	11/12/2024	Common Stock	10,834	\$ 1.68	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	01/26/2025	Common Stock	15,500	\$ 2.14	D	Â
Stock Option (Right to Buy)	Â <u>(4)</u>	01/22/2026	Common Stock	30,000	\$ 2.72	D	Â
Stock Option (Right to Buy)	Â <u>(5)</u>	10/03/2026	Common Stock	30,000	\$ 3.67	D	Â
Stock Option (Right to Buy)	Â <u>(6)</u>	01/24/2027	Common Stock	44,888	\$ 2.1	D	Â
Stock Option (Right to Buy)	Â <u>(6)</u>	01/24/2027	Common Stock	10,000	\$ 2.1	D	Â
Stock Option (Right to Buy)	Â <u>(1)</u>	01/24/2027	Common Stock	112	\$ 2.1	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
	Â	Â	Â Principal Accounting Officer	Â

Cabatuan Nelson
RIGEL PHARMACEUTICALS, INC.
1180 VETERANS BLVD.
SOUTH SAN FRANCISCO, CA 94080

Signatures

/s/ Nelson

12/22/2017

Cabatuan

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This option is fully vested.
- (2) This option vests monthly over four (4) years from January 1, 2014.
- (3) This option vests monthly over four (4) years from October 1, 2014.
- (4) This option vests monthly over two (2) years from January 1, 2016.
- (5) This option vests monthly over four (4) years from October 3, 2016.
- (6) This option vests monthly over four (4) years from January 1, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.